Has Aurobindo Pharma left its wild swings behind?
The Hyderabad-based generics maker has seen its stock scale all-time highs and lows in quick succession. With big plans in place and regulatory heat easing, its roller-coaster days may be over.
29 November, 2023•6 min
0
29 November, 2023•6 min
0
Getting your Trinity Audio player ready...
More in Business
Business
NSE’s IPO bankers likely to run into a seller problem
Many of its 186,000 eligible shareholders are unlikely to sell their stock in the upcoming offer-for-sale—opting to resist formal price discovery and wait it out instead.
You may also like
Business
Natco just can’t kick its high-risk, high-gain game plan
CEO Rajeev Nannapaneni’s oft-used strategy of mounting patent challenges in the US got the pharma company its latest blockbuster Revlimid. But what after sales fall off a cliff?
Business
Wockhardt urgently needs Rs 400 crore and its two wonder drugs
A couple of antibiotics that have the potential to change the beleaguered company’s fortunes need a quick infusion of funds to get across the finish line. Can Khorakiwala, the 82-year-old chairman, pull it off?
Business
Laurus Labs is Indian pharma’s dark horse
With a promoter who is unafraid to make bold bets and pivot to businesses holding more promise, investors can only look forward to better times.